Real Survival Benefit of CDK4/6 Inhibitors in CSM

Published Date: 02 Mar 2023

Registry data support an overall survival benefit of adding CDK4/6 inhibitors to hormone therapy in HR-positive metastatic breast cancer.

Read Full News

Latest News



Latest News


News All Time

HTTP error: 503HTTP error: 503HTTP error: 503
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

2.

Clinical trial is testing whether heavy lifting could combat cancer side effects

3.

NIH research cuts leave cancer patient facing hard choice

4.

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

5.

A video animation guide to assist young people who are fatigued from cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot